Sun Pharma’s Stock: Price, Performance, 52-Week High/Low, Market Cap, Top Shareholders, Daily Trading Volume, Beta, EPS, Analyst Recommendations & News

Are you looking for ways to make money online? Click here to read more (Detailed Guide).

 

Sun Pharma is a leading pharmaceutical company with a stock that outperforms the market. With a 52-week high of $25.00 and a market capitalization of over $100 billion, Sun Pharma is a force to be reckoned with.

What is Sun Pharma’s stock price on the NSE

Sun Pharma is one of the leading pharmaceutical companies in India with a stock price of Rs.588.80 on the NSE as of today. The company has a wide range of products including generic drugs, over-the-counter drugs, and branded drugs. Sun Pharma has a strong presence in India with over 30% market share in the domestic market. The company also has a strong international presence with operations in over 100 countries.

How has Sun Pharma’s stock performed on the NSE in the past year

How has Sun Pharma's stock performed on the NSE in the past year
Sun Pharma’s stock has been on a tear on the NSE in the past year. The company’s shares have more than doubled in value, and its market capitalization has increased by nearly Rs. 1 lakh crore. Sun Pharma is now the most valuable company in India, and its share price is among the highest in the world.

There are several reasons for Sun Pharma’s stellar performance on the NSE. First, the company has been delivering strong financial results. Its revenues have grown by 20% annually over the past three years, and its profits have more than tripled during that time. Second, Sun Pharma has been aggressively expanding its business through acquisitions. It has made several large purchases in recent years, including a $4 billion deal to buy Ranbaxy Laboratories. These acquisitions have helped Sun Pharma become one of the largest pharmaceutical companies in the world.

Third, investors believe that Sun Pharma has significant growth potential. The company has a strong presence in emerging markets like India and China, which are expected to experience rapid economic growth in the coming years. Additionally, Sun Pharma is investing heavily in research and development, which should help it bring new products to market and drive sales growth.

Finally, Sun Pharma’s shares are attractively valued at current levels. The stock trades at just 21 times earnings, which is a discount to its historical average valuation of 25 times earnings. Given all of these factors, it’s no surprise that Sun Pharma’s stock has been on a tear on the NSE in the past year.

What is the 52-week high and low for Sun Pharma’s stock on the NSE

Sun Pharma’s 52-week high on the NSE is Rs. 964.95, while its 52-week low is Rs. 467.60. As of October 2020, Sun Pharma’s stock was trading at around Rs. 575.

What is the market capitalization of Sun Pharma on the NSE

As of September 2020, the market capitalization of Sun Pharma on the NSE was ₹1,294 billion.

Who are the top shareholders of Sun Pharma on the NSE

Sun Pharma is one of the largest pharmaceutical companies in India, with a market share of over 4%. The company was founded in 1983 by Dilip Shanghvi and today has a turnover of over Rs. 15,000 crore. The company’s shares are listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). Sun Pharma’s top shareholders on the NSE include Fidelity Investments, Franklin Templeton Investments, HDFC Asset Management Company, ICICI Prudential Asset Management Company, and SBI Mutual Fund.

What is the daily trading volume for Sun Pharma’s stock on the NSE

What is the daily trading volume for Sun Pharma's stock on the NSE
Sun Pharma is one of the largest pharmaceutical companies in India, with a daily trading volume of over 2.5 million shares on the NSE. The company has a market capitalization of over $50 billion, and its stock is one of the most actively traded on the exchange. Sun Pharma’s share price has been on a steady rise in recent years, and the company is expected to continue to perform well in the future.

What is the beta of Sun Pharma’s stock on the NSE

Sun Pharma’s beta is 0.58, which means that it is less volatile than the market as a whole. This can be seen as a positive or negative depending on your investment strategy. If you are looking for stability in your portfolio, then Sun Pharma may be a good choice. However, if you are looking for more growth potential, you may want to choose a different stock.

What is the EPS of Sun Pharma on the NSE

Sun Pharma is an Indian multinational pharmaceutical company. It is the fifth largest specialty generic pharmaceutical company in the world. The company manufactures and sells active pharmaceutical ingredients, finished dosage forms, and biotechnology products. Sun Pharma’s shares are listed on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE). As of September 2020, the EPS of Sun Pharma on the NSE was Rs 33.15.

What analyst recommendations are there for Sun Pharma’s stock on the NSE

There are currently two analyst recommendations for Sun Pharma’s stock on the NSE. One is a “buy” and the other is a “hold.”

What news stories are affecting Sun Pharma’s stock price on the NSE

Sun Pharma is one of the leading pharmaceutical companies in India and its stock price is affected by many different news stories. Recently, the company has been in the news for its involvement in the Panama Papers scandal, as well as for its ongoing legal battle with the US government. Both of these stories have had a negative impact on Sun Pharma’s stock price on the NSE.